RETATRUTIDE

Retatrutide – Research Grade Peptide

Retatrutide is an investigational amino acid peptide studied as a triple hormone receptor agonist, simultaneously targeting the GLP-1, GIP, and glucagon receptors to evaluate comprehensive metabolic effects in research.

Product Details

• Synonyms: LY-3437943; Retatrutide
  
• CAS Number: 2381089-83-2
  
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
  
• Molecular Weight: 4731.33 g/mol
  
• Solubility: Soluble in water (lyophilized peptide reconstitutes in saline or buffer); handle gently to avoid degradation

Background: Retatrutide is an investigational triple hormone agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. It is designed to push the envelope of metabolic therapy by not only enhancing insulin secretion and reducing appetite (GLP-1, GIP effects) but also raising energy expenditure and fat oxidation (via glucagon receptor activation). In essence, retatrutide seeks to combine the benefits of incretins with a mild glucagon-induced metabolic boost. Clinical evidence: A Phase 2 trial in adults with obesity (no diabetes) reported staggering weight loss results. At the highest dose (12 mg weekly), retatrutide achieved over 24% mean body weight reduction in 48 weeks – nearly a quarter of body weight lost on average. Even at 4–8 mg doses, substantial weight drops were seen, and remarkably every single patient on 8 mg or 12 mg lost at least 5% weight, with the majority far exceeding that. For context, these outcomes appear even greater than those of tirzepatide over a similar time frame. A lead investigator noted patients on high-dose retatrutide lost nearly 60 lbs in 11 months, highlighting the potential of this tri-agonist therapy. The drug also showed benefits in a NAFLD (fatty liver) substudy: ~90% of patients on high doses had resolution of liver fat, pointing to powerful effects on ectopic fat as well

References:
[1] https://diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium

For Research Use Only. This product is supplied for scientific research and laboratory use only, not for human or veterinary administration.

Download COA